Akouos, Inc (AKUS)

Etorro trading 970x250
Akouos, Inc (AKUS) Logo

About Akouos, Inc

Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company’s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts. Address: 645 Summer Street, Boston, MA, United States, 02210

Akouos, Inc News and around…

Latest news about Akouos, Inc (AKUS) common stock and company :

This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
16 Aug, 2022 FinancialContent

Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the ...

Akouos: Q2 Earnings Insights
15 Aug, 2022 FinancialContent

Akouos (NASDAQ:AKUS) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors ...

Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights
15 Aug, 2022 Yahoo! Finance

Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear Received a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 million BOSTON, Aug. 1

Analysts Expect BIB Will Reach $78
11 Aug, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the BIB ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $77.55 per unit.

Tesla, Twitter And 76 Biggest Movers From Friday
11 Jul, 2022 FinancialContent

Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as ...

Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
05 Jul, 2022 FinancialContent

Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to ...

12 Health Care Stocks Moving In Friday's Intraday Session
01 Jul, 2022 FinancialContent

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares moved upwards by 38.8% to $0.62 during Friday's regular session. ...

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
30 Jun, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company ...

Stocks Remain Shaky Midweek, Dow Sporting Muted Gains
29 Jun, 2022 FinancialContent

As the first half of 2022 draws to an end, stocks continue to struggle for direction.

U.S. Stocks Turn Negative; 2U Shares Spike Higher
29 Jun, 2022 FinancialContent

U.S. stocks pared gains midway through trading, with all the three major indicesturning lower on Wednesday. The Dow traded ...

Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
29 Jun, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its ...

Zendesk, Quotient, + 40 Stocks Moving In Friday's Mid-Day Session
24 Jun, 2022 FinancialContent

Gainers USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and ...

91 Biggest Movers From Friday
13 Jun, 2022 FinancialContent

Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced ...

79 Biggest Movers From Yesterday
08 Jun, 2022 FinancialContent

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
07 Jun, 2022 FinancialContent

Gainers Kiromic BioPharma (NASDAQ:KRBP) shares moved upwards by 77.3% to $0.5 during Tuesday's regular session. ...

We're Keeping An Eye On Akouos' (NASDAQ:AKUS) Cash Burn Rate
30 May, 2022 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
19 May, 2022 Yahoo! Finance

- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical development of AK-OTOF for the treatment of OTOF-mediated hearing loss - MicroRNA target site (miR-TS)-incorporation in AAV vectors is shown to have potential benefits for de-targeting transgene expression in the inner ear, supporting future development of gene therapies targeting a broad range of inner

Akouos: Q1 Earnings Insights
12 May, 2022 FinancialContent

Akouos (NASDAQ:AKUS) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need ...

Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights
12 May, 2022 Yahoo! Finance

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of microRNA target sites in AAV vectors for regulated gene expression in the inner ear - Presented new nonclinical data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions -Ended the fir

Akouos to Present at Bank of America 2022 Healthcare Conference
04 May, 2022 Yahoo! Finance

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada. A live webcast

Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting
03 May, 2022 Yahoo! Finance

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which will take place in Washington, D.C. (both in-person and virtually) from May 16 to 19, 2022. The company will give two presentations at the

Recap: Akouos Q4 Earnings
29 Mar, 2022 FinancialContent

Akouos (NASDAQ:AKUS) reported its Q4 earnings results on Tuesday, March 29, 2022 at 08:00 AM. Here's what investors ...

Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
29 Mar, 2022 Yahoo! Finance

- Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presented data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions - Expanded leadership team with appointment of otology leader Aaron Tward, M.D., Ph.D., as chief scientific officer - Ended 2021 with a strong cash position of $232.5 million BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (Nasdaq: AKUS), a precision g

Akouos to Participate in Upcoming March Virtual Investor Conferences
24 Mar, 2022 Yahoo! Finance

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March: H.C. Wainwright Gene Therapy and Gene Editing Conference Pre-recorded presentation available for

Analysts Expect 29% Gains Ahead For VTWO
22 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $107.06 per unit.

Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer
10 Mar, 2022 Yahoo! Finance

BOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer. Dr. Tward is a surgeon and a scientist with deep experience in genetics, genomics, gene delivery, high-throughput sequencing technologies, and the clinical care of patients with conditions o

RSI Alert: Akouos (AKUS) Now Oversold
03 Mar, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Akouos to Present at Cowen 42nd Annual Heath Care Conference
01 Mar, 2022 Yahoo! Finance

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a panel discussion titled Auditory and Ophthalmology at the Cowen 42nd Annual Health Care Conference on Monday, March 7 at 2:10 p.m. EST.

How The Parts Add Up: UWM Targets $62
16 Feb, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Russell2000 ETF (UWM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $61.55 per unit.

Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting
07 Feb, 2022 Yahoo! Finance

- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of vestibular schwannoma - AAVAnc80 and a supporting cell selective promoter can drive widespread GJB2 expression in supporting cells, while limiting expression in, and loss of, hair cells in mice - AAV-mediated RNAi gene silencing and CRISPR/Cas9 gene editing methods demonstrate a promising reduction of gene of interest protein expression, which

Akouos, Inc (AKUS) is a NASDAQ Common Stock listed in , ,

970x250